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Abstract
We used molecular techniques to analyse 87 (n = 70 patients)
Aspergillus terreus complex isolates, all of which were identiﬁed
as A. terreus sensu stricto. The antifungal susceptibilities deter-
mined with CLSI M38-A2 (and Etest for amphotericin B) and
expressed as mg/L for range of MIC/MIC90/geometric mean
were as follows: itraconazole, 0.25–2/2/1.097; voriconazole,
0.125–2/2/1.176; posaconazole, 0.25–1/1/0.836; amphotericin B
CLSI, 4–32/16/9.689; and Etest, 0.75–64/6/3.106. The MICs for
amphotericin B were signiﬁcantly higher than those found for
the triazoles.
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Aspergillus fumigatus is the most frequent cause of invasive
aspergillosis, although other species with variable antifungal
susceptibility patterns are emerging [1–3]. Aspergillus terreus,
a species with known antifungal resistance to amphotericin B,
is a clinically relevant cause of invasive aspergillosis in some
hospitals [4–7].
Recent phylogenetic studies have shown that Aspergillus
section Terrei includes the species A. terreus sensu stricto,
Aspergillus carneus, Aspergillus niveus, Aspergillus alabamensis,
and A. terreus var. aureus [8,9]. These species are morpholog-
ically indistinguishable, and can only be identiﬁed with molec-
ular techniques. In addition, molecular identiﬁcation helps us
to better understand the epidemiology of invasive aspergillo-
sis [5]. To date, with the exception of A. niveus, A. terreus
sensu stricto has been the only species of the complex
reported to cause invasive aspergillosis [10]. However, few
studies have used molecular techniques to identify clinical
isolates.
We studied 87 clinical samples (excluding otic exudates
and other superﬁcial samples) in which A. terreus was iso-
lated. The samples were collected from 70 patients admitted
to our institution between October 2005 and March 2010.
We selected one isolate per sample. The samples were
obtained from the respiratory tract (n = 65; 74.7%), biopsy
specimens (n = 6; 6.9%), sterile ﬂuids (n = 6; 6.9%), wounds
(n = 6; 6.9%), and other sites (n = 4; 4.6%). Patients were
classiﬁed according to the criteria of the European Organiza-
tion for Research and Treatment of Cancer [11] as having
proven invasive aspergillosis (n = 3), probable invasive asper-
gillosis (n = 8), or non-invasive aspergillosis.
All of the isolates were morphologically identiﬁed as A. ter-
reus complex and stored. Isolates were regrown on potato
dextrose agar plates. Genomic DNA of the strains was
extracted from conidial suspensions with the DNeasy Tissue
kit (Qiagen, Hilden, Germany), and initially treated with lyti-
case (Sigma-Aldrich, St Louis, MO, USA) for 2 h at 37C.
For molecular identiﬁcation, we partially ampliﬁed the ITS1–
5.8S–ITS2 region (primers ITS-1 and ITS-4) and the b-tubulin
gene [12,13]. Double-stranded DNA sequencing of the prod-
ucts of PCR was carried out in a 3130xl analyzer (Applied
Biosystems, Foster City, CA, USA). A BLAST search of all of
the sequences was performed to identify the isolates. In
order to investigate the presence of cryptic species, we per-
formed a phylogenetic study including a partially ampliﬁed
sequence of the ITS1–5.8S–ITS2 region and the b-tubulin,
enolase and calmodulin genes [9]. The neighbour-joining
method [14] was used to construct the phylogenetic tree
based on the four regions sequenced. The data were ﬁrst
analysed by use of the Tamura–Nei parameter distance cal-
culation model with gamma-distributed substitution rates
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[15], and the neighbour-joining tree was constructed with
MEGA version 4 [16]. A bootstrap analysis with 1000 repli-
cations was performed to determine the support for each
clade. Reference sequences retrieved from GenBank were
included. A clinical isolate of Neosartorya udagawae was
included as an outgroup.
Antifungal susceptibilities to itraconazole (Janssen Pharma-
ceutical, Madrid, Spain), voriconazole (Pﬁzer Pharmaceutical
Group, New York, NY, USA), posaconazole (Merck
Research Laboratories, Rahway, NJ, USA) and amphoteri-
cin B (Sigma, Madrid, Spain) were tested according to the
CLSI M38-A2 procedure. The antifungal activity of amphoter-
icin B was also obtained by means of the Etest (bioMe´rieux,
Lyon, France). A. fumigatus (ATCC05) and Aspergillus ﬂavus
(ATCC04) were included as quality controls.
During the study period, we recorded 69 cases of proven/
probable invasive aspergillosis with clinical isolation of Asper-
gillus species. A. fumigatus was found in most cases (72.4%).
Although A. terreus was involved in 16% of the episodes, it
was usually found as a co-pathogen with A. fumigatus or
other moulds. Molecular identiﬁcation with the ITS region
and b-tubulin gene proved that all isolates were A. terreus
sensu stricto. The phylogenetic analysis revealed that all iso-
lates were included in the same clade (bootstrap value of
97%). A similar tree was obtained when the ITS region was
removed, showing that this region yielded limited phylo-
genetic information. Only one of the isolates had the A. terreus
var. africanus reference sequence (bootstrap value of 82%)
(Fig. 1). The high bootstrap value suggests that this isolate
was A. terreus var. africanus, a rarely found variety of A. terre-
us complex. This isolate was obtained from a respiratory
sample of a patient with exacerbated chronic obstructive pul-
monary disease, and the isolation was considered to be non-
signiﬁcant. The taxonomic status of A. terreus var. africanus
remains unresolved, and extensive analysis on this variety is
necessary [8,9].
The antifungal activities of itraconazole, voriconazole, po-
saconazole and amphotericin B against the 87 isolates are
shown in Table 1. None of the isolates showed an MIC of
>2 mg/L for itraconazole and voriconazole or >1 mg/L for
posaconazole. In contrast, the MICs of amphotericin B were
signiﬁcantly higher than those found for the three triazoles
(p <0.001), regardless of the method chosen. A. terreus is










FIG. 1. Neighbour-joining tree generated from partial sequences in
the ITS regions and b-tubulin, enolase and calmodulin genes.
TABLE 1. MICs of itraconazole, voriconazole and posaco-
nazole against the 87 Aspergillus terreus isolates obtained
with the CLSI M38-A2 procedure
MIC (mg/L)
Range GM MIC50 MIC90
Itraconazole 0.25–2 1.087 1 2
Voriconazole 0.125–2 1.167 1 2
Posaconazole 0.250–1 0.834 1 1
Amphotericin B CLSI 4–32 9.617 8 16
Amphotericin B Etest 0.750–64 3.073 1.5 6
GM, geometric mean.
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poorer in patients with invasive aspergillosis who receive
antifungal treatment with this agent [17,18].
We conclude that all A. terreus complex isolates causing
invasive aspergillosis or colonization were A. terreus sensu
stricto. In most cases of invasive aspergillosis, A. terreus was
considered to be a co-pathogen occurring alongside A. fumig-
atus. The isolates showed antifungal resistance to amphoteri-
cin B and remained fully susceptible to the triazoles.
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